Topic: cystic fibrosis

Vertex Pharma

31. Trikafta

With its five-months-early FDA approval for Trikafta, Vertex ushered in the triple combo era in cystic fibrosis—and majorly expanded its treatable population in the process.
Symdeko

3. Symdeko

Symdeko doesn’t require specific blood-pressure monitoring, nor does it carry a warning about respiratory events, as Vertex's older treatment Orkambi does.